The most common gain-of-function mutations identified in LGLL patients are on STAT3 and STAT5b genes, which have been recently recognized as clonal markers and were included in the 2017 WHO classification of the disease. This evidence concerns the gene STAT3 and T-cell large granular lymphocyte leukemia.